T
Tactiva Therapeutics
Developing next generation adoptive cell therapy strategies that deliver lethal hits to cancer cells
About Tactiva Therapeutics
Tactiva Therapeutics is a pioneering immuno-oncology company focused on developing advanced cancer immunotherapies. Specializing in adoptive cell therapy (ACT), Tactiva employs a dual T cell receptor approach to reprogram patients' own T cells to recognize, attack, and destroy cancer cells. This strategy aims to provide a robust and sustained immune response against tumors. The company primarily serves patients battling various forms of cancer, operating within the biopharmaceutical market. Tactiva's business model revolves around the research, development, and clinical application of its proprietary immunotherapy technologies. Revenue is generated through clinical trials, partnerships, and potential future commercialization of its therapies. The company's leadership includes experienced professionals with extensive backgrounds in biopharma and academia, ensuring strong guidance and innovative research.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 5
- Open positions
- None listed
- Dealroom signal
- 56.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, Cancer Care Companion, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2018 | $35M | $140M | Efung Capital · Panacea Venture · Viventures | ↗ |
| SEEDEquity / VC | Jul 2016 | $1.5M | $6M | Undisclosed | — |
Growth signals
Latest recorded traffic for Tactiva Therapeutics is 980 monthly website visits, up 216.1% over the last three months. Tactiva Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tactiva Therapeutics in the Buffalo ecosystem
The Tactiva Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Panacea Venture- ECEfung Capital
- VIViventures
Other known investors1 additional known investor
University of Buffalo
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tactiva Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tactiva Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










